Treatment of agnogenic myeloid metaplasia with danazol: A report of four cases
article
OA: bronze
CC0
AI-generated summary
Danazol treatment in four patients with agnogenic myeloid metaplasia and severe cytopenias reduced transfusion dependence and improved other blood counts and splenomegaly without observed side effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400–600 mg/day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action. © 1996 Wiley-Liss, Inc.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
References (6)
- Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases via openalex
- Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. via openalex
- Danazol in the treatment of myelodysplastic syndromes via openalex
- doi:10.1111/j.1365-2141.1993.tb08681.x via openalex
- doi:10.1111/j.1365-2141.1994.tb04802.x via openalex
- doi:10.3109/07357909709115771 via openalex
Source provenance
- openalex
- last seen: 2026-05-10T11:27:16.268313+00:00
License: CC0
· commercial use OK